In the pharmacokinetic phase I study in cancer patients, quercetin was well tolerated (Ferry et al, 1996), and there was evidence of pharmacodynamic activity as indicated by inhibition of epidermal growth factor receptor phosphorylation, yet indications of nephrotoxicity were also observed. Here, EGFR is linked to cancer.